Chi­nese phar­ma groups part­ner in $150M li­cens­ing deal; Pfiz­er to join law­suit on tar­iffs

Chi­nese phar­ma group Al­pham­ab On­col­o­gy an­nounced yes­ter­day that its sub­sidiary signed a con­tract worth po­ten­tial­ly as much as $150 mil­lion with JMT-Bio, a sub­sidiary of CSPC Phar­ma­ceu­ti­cal Group, to de­vel­op and com­mer­cial­ize an an­ti-HER2 bis­pe­cif­ic an­ti­body KN026 in Chi­na.

JMT will bear the costs of all clin­i­cal tri­als in­volv­ing KN026 in Main­land Chi­na in ex­change for ex­clu­sive li­cens­ing rights of KN026 on in­di­ca­tions of breast can­cer and gas­tric or gas­troe­sophageal junc­tion can­cers. In ad­di­tion, Jiang­su and JMT will col­lab­o­rate on de­vel­op­ing more po­ten­tial in­di­ca­tions of KN026.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER